Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Orphan Drug market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 6.1% during the forecast period.
This report presents the market size and development trends by detailing the Orphan Drug market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Orphan Drug market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Orphan Drug industry and will help you to build a panoramic view of the industrial development.
Orphan Drug Market, By Type:
Type 1
Type 2
Type 3
Orphan Drug Market, By Application:
End-User 1
End-User 2
End-User 3
Some of the leading players are as follows:
AGENUS
AOP ORPHAN
ELI LILLY
Roche
PFIZER
MERCK
GENETHON
Celgene
BIOGEN IDEC
BRISTOL MYERS SQUIBB
GENZYME CORPORATION
ALEXION
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Orphan Drug Market: Technology Type Analysis
-
4.1 Orphan Drug Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Orphan Drug Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Type 1
4.3.2 Type 2
4.3.3 Type 3
5 Orphan Drug Market: Product Analysis
-
5.1 Orphan Drug Product Market Share Analysis, 2018 & 2026
-
5.2 Orphan Drug Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Orphan Drug Market: Application Analysis
-
6.1 Orphan Drug Application Market Share Analysis, 2018 & 2026
-
6.2 Orphan Drug Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 End-User 1
6.3.2 End-User 1
6.3.3 End-User 3
7 Orphan Drug Market: Regional Analysis
-
7.1 Orphan Drug Regional Market Share Analysis, 2018 & 2026
-
7.2 Orphan Drug Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 AGENUS
9.1.1 AGENUS Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 AOP ORPHAN
9.2.1 AOP ORPHAN Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 ELI LILLY
9.3.1 ELI LILLY Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Roche
9.4.1 Roche Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 PFIZER
9.5.1 PFIZER Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 MERCK
9.6.1 MERCK Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 GENETHON
9.7.1 GENETHON Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 Celgene
9.8.1 Celgene Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 BIOGEN IDEC
9.9.1 BIOGEN IDEC Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 BRISTOL MYERS SQUIBB
9.10.1 BRISTOL MYERS SQUIBB Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 GENZYME CORPORATION
9.11.1 GENZYME CORPORATION Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 ALEXION
9.12.1 ALEXION Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
The List of Tables and Figures (Totals 74 Figures and 128 Tables)
Figure Type 1 Orphan Drug market, 2015 - 2026 (USD Million)
Figure Type 2 Orphan Drug market, 2015 - 2026 (USD Million)
Figure Type 3 Orphan Drug market, 2015 - 2026 (USD Million)
Figure End-User 1 market, 2015 - 2026 (USD Million)
Figure End-User 2 market, 2015 - 2026 (USD Million)
Figure End-User 3 market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Orphan Drug market, by country, 2015 - 2026 (USD Million)
-
Table North America Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table North America Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table North America Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table Canada Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table Canada Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Europe Orphan Drug market, by country, 2015 - 2026 (USD Million)
-
Table Europe Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table Europe Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table Europe Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table Germany Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table Germany Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table France Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table France Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table Italy Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table Italy Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table Spain Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table Spain Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Orphan Drug market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table China Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table China Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table Japan Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table Japan Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table India Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table India Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Orphan Drug market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table MEA Orphan Drug market, by country, 2015 - 2026 (USD Million)
-
Table MEA Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table MEA Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table MEA Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Orphan Drug market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Orphan Drug market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Orphan Drug market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table AGENUS Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table AOP ORPHAN Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table ELI LILLY Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Roche Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table PFIZER Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table MERCK Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table GENETHON Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Celgene Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table BIOGEN IDEC Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table BRISTOL MYERS SQUIBB Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table GENZYME CORPORATION Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table ALEXION Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
